Results 161 to 170 of about 61,886,207 (255)

POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, Volume 101, Issue 10, Page 2632-2651, October 2026.
ABSTRACT Disease Overview POEMS syndrome is a life‐threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease.
Angela Dispenzieri
wiley   +1 more source

Retinoic Acid Receptor γ Is a Ligand-Activated Gatekeeper to Stem Cell Developmental Progression. [PDF]

Int J Mol Sci
Johnson WEB, McQueen C, Brown G.
europepmc   +1 more source

Do Stimulants Promote Arrhythmic Risk: Insights From a Human‐Induced Pluripotent Stem Cell‐Derived Cardiomyocyte Model

Journal of Arrhythmia, Volume 42, Issue 5, October 2026.
At clinically relevant plasma concentrations, stimulant medications produced minimal effects on conduction velocity but modulated automaticity and repolarization in a hiPSC‐derived cardiomyocyte (hiPSC‐CM) model. These findings provide a foundation for future investigations of stimulant‐associated cardiac safety and support the utility of hiPSC‐CM ...
Alia Arslanova, Samantha Wong, Sonia Franciosi, Glen F. Tibbits, Maksymilian Prondzynski, Shubhayan Sanatani   +5 more
wiley   +1 more source

Stable simulations do not guarantee functional engagement: a case study of off-target prediction for Seladelpar and Zanamivir. [PDF]

J Comput Aided Mol Des
Kemp R, Kean TJ, Medvedev KE.
europepmc   +1 more source

The CRABP2–MDK Signaling Axis Promotes Lung Adenocarcinoma (LUAD) Progression and Highlights Prognostic Biomarkers

Molecular Carcinogenesis, Volume 65, Issue 10, Page 1163-1182, October 2026.
ABSTRACT Lung cancer is the leading cause of cancer‐related mortality worldwide, with LUAD being characterized by high incidence and mortality rates. Despite the use of various treatments, including surgery, chemotherapy, immunotherapy, and molecular targeted therapy, the prognosis in LUAD patients remains unfavorable.
Jingshun Zhang, Cui Zhang, Guopeng Jiang, Xia Liu, Yifan Li, Fuman Wang, Xuefei Sun, Peidao Sun   +7 more
wiley   +1 more source

Ganaxolone, an approved therapy for CDKL5-deficiency disorder, is an inhibitor of PTP1B. [PDF]

J Biol Chem
Zubiete-Franco I, Hu Q, Alves SR, Utama R, Tonks NK.   +4 more
europepmc   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, Volume 270, Issue 2, Page 139-162, October 2026.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source

Vitamins as modulators of neonatal intestinal injury. [PDF]

Front Nutr
Singh DK, Yamaguchi Y, Saito C, Cassidy OG, Nishiyama K, Huang L.   +5 more
europepmc   +1 more source

SIRT1 in Neurodegenerative Diseases: Molecular Mechanisms, Disease Relevance, and Therapeutic Potential

The FASEB Journal, Volume 40, Issue 17, 15 September 2026.
SIRT1, an NAD+‐dependent deacetylase, supports cognitive resilience by coordinating neuroprotection, synaptic plasticity, autophagy–lysosomal proteostasis, and mitochondrial energy homeostasis. Reduced or dysregulated SIRT1 is associated with protein aggregation, neuroinflammation, mitochondrial dysfunction, synaptic loss, and cognitive decline in ...
Jiabin Duan, Jiaqi Liu, Qingsheng Meng, Jiahao Liu, Sitian Yang, Fang Zhou, Jing Cao   +6 more
wiley   +1 more source